Overcoming PI3K Inhibitor Resistance in Advanced ER+ Breast Cancer
Advanced estrogen receptor-positive (ER+) breast cancer often develops resistance to current treatments that combine endocrine therapy with CDK4/6 or PI3K/AKT/mTOR inhibitors. Once this happens, treatment options are limited, and new strategies are urgently needed. Research shows that these pathways work together to drive tumor growth, suggesting that blocking all three pathways at the same time […]